サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：HIVおよびHBV治療薬の世界市場（2022年～2032年）
市場調査レポート
商品コード
1157859

HIVおよびHBV治療薬の世界市場（2022年～2032年）

HIV and HBV Therapies Market Report 2022-2032
出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 353 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=198.76円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

HIVおよびHBV治療薬の世界市場（2022年～2032年）
出版日: 2022年11月11日
発行: Visiongain Reports Ltd.
ページ情報: 英文 353 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のHIVおよびHBV治療薬の市場規模は、2022年には362億米ドルと推定され、予測期間2022-2032年にはCAGR6.5％で成長すると予測されています。

同市場を促進する主な要因は、HIVおよびHBVの有病率の上昇、研究開発への高い投資、政府支援の拡大などです。主な課題には、投資の必要性、研究件数の多さ、これらの生物および疾患の臨床的側面が膨大であることが挙げられます。

当レポートでは、世界のHIVおよびHBV治療薬市場について調査し、市場規模や予測、市場力学、セグメント・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な調査結果
  • 市場力学
    • 市場の促進要因
    • 市場の抑制要因
    • 市場機会
  • COVID-19影響分析
  • ポーターのファイブフォース分析

第4章 世界のHIVおよびHBV治療薬市場分析：薬剤クラス別

  • 主な調査結果
  • 薬剤クラスセグメントの成長見通し
  • 世界のHIVおよびHBV治療薬の市場規模推計・予測：薬剤クラス別
  • 併用療法
  • ヌクレオシドおよび非ヌクレオシド RTI
  • インテグラーゼ阻害剤
  • プロテアーゼ阻害剤
  • その他

第5章 世界のHIVおよびHBV治療市場分析：流通チャネル別

  • 主な調査結果
  • 流通チャネルセグメントの成長見通し
  • 世界のHIVおよびHBV治療薬の市場規模推計・予測：流通チャネル別
  • 世界のHIVおよびHBV治療市場シェア（2022年、2032年）：流通チャネル別
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第6章 世界のHIVおよびHBV治療薬市場のパイプライン分析

  • 主な調査結果
  • HIVパイプライン
  • HBVパイプライン

第7章 世界のHIVおよびHBV治療薬市場分析：地域別

  • 主な調査結果
  • 地域の市場規模推計・予測
  • COVID-19影響分析：回復シナリオ（V、U、W、L）

第8章 北米のHIVおよびHBV治療薬市場分析

  • 主な調査結果
  • HIVおよびHBV治療薬市場の魅力指数
  • HIVおよびHBV治療薬市場：国別（2022年、2027年、2032年、金額）
  • HIVおよびHBV治療薬市場規模推計・予測：国別
  • HIVおよびHBV治療薬市場規模推計・予測：薬剤クラス別
  • HIVおよびHBV治療薬市場規模推計・予測：流通チャネル別
  • 米国
  • カナダ

第9章 欧州のHIVおよびHBV治療薬市場分析

  • 主な調査結果
  • HIVおよびHBV治療薬市場の魅力指数
  • HIVおよびHBV治療薬市場：国別（2022年、2027年、2032年、金額）
  • HIVおよびHBV治療薬市場規模推計・予測：国別
  • HIVおよびHBV治療薬市場規模推計・予測：薬剤クラス別
  • HIVおよびHBV治療薬市場規模推計・予測：流通チャネル別
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • ロシア
  • その他

第10章 アジア太平洋地域のHIVおよびHBV治療薬市場分析

  • 主な調査結果
  • HIVおよびHBV治療薬市場の魅力指数
  • HIVおよびHBV治療薬市場：国別（2022年、2027年、2032年、金額）
  • HIVおよびHBV治療薬市場規模推計・予測：国別
  • HIVおよびHBV治療薬市場規模推計・予測：薬剤クラス別
  • HIVおよびHBV治療薬市場規模推計・予測：流通チャネル別
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • その他

第11章 ラテンアメリカのHIVおよびHBV治療薬市場分析

  • 主な調査結果
  • HIVおよびHBV治療薬市場の魅力指数
  • HIVおよびHBV治療薬市場：国別（2022年、2027年、2032年、金額）
  • HIVおよびHBV治療薬市場規模推計・予測：国別
  • HIVおよびHBV治療薬市場規模推計・予測：薬剤クラス別
  • HIVおよびHBV治療薬市場規模推計・予測：流通チャネル別
  • ブラジル
  • メキシコ
  • その他

第12章 中東・アフリカのHIVおよびHBV治療薬市場分析

  • 主な調査結果
  • HIVおよびHBV治療薬市場の魅力指数
  • HIVおよびHBV治療薬市場：国別（2022年、2027年、2032年、金額）
  • HIVおよびHBV治療薬市場規模推計・予測：国別
  • HIVおよびHBV治療薬市場規模推計・予測：薬剤クラス別
  • HIVおよびHBV治療薬市場規模推計・予測：流通チャネル別
  • 南アフリカ
  • GCC諸国
  • その他

第13章 競合情勢

  • 企業シェア分析
  • 主要ビジネス戦略分析

第14章 企業プロファイル

  • Pfizer
  • Merck
  • GSK
  • AbbVie
  • Boehringer Ingelheim
  • Gilead Sciences
  • Janssen Pharma
  • Teva
  • BMS
  • Arbutus Biopharma

第15章 結論と提言

  • おわりに
  • 市場関係者への推奨事項
図表

List of Tables

  • Table 1 Global HIV and HBV Therapies Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
  • Table 2 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (V-shaped Recovery)
  • Table 3 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (U-shaped Recovery)
  • Table 4 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (W-shaped Recovery)
  • Table 5 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (L-shaped Recovery)
  • Table 6 HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 7 Approved Combination Therapies
  • Table 8 Combination Therapies Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 9 Approved NRTIs
  • Table 10 Approved NNRTIs
  • Table 11 Nucleoside and Non-nucleoside RTIs Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 12 Approved Integrase Inhibitors
  • Table 13 Integrase Inhibitors Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 14 Approved Protease Inhibitors
  • Table 15 Protease Inhibitors Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 16 Approved other therapies
  • Table 17 Other Drug Class Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 18 HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 19 Hospital pharmacies Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 20 Retail pharmacies Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 21 Online pharmacies Market, by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 22 HIV Pipeline Products
  • Table 23 HIV Pipeline Products (bNAbs)
  • Table 24 HIV Pipeline Products (other compounds)
  • Table 25 Chronic Hepatitis B pipeline, 2022
  • Table 26 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 27 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (V-shaped Recovery)
  • Table 28 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (U-shaped Recovery)
  • Table 29 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (W-shaped Recovery)
  • Table 30 HIV and HBV Therapies Market, By Region, 2022-2032 (US$ Bn, AGR %, CAGR %) (L-shaped Recovery)
  • Table 31 North America HIV and HBV Therapies Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 32 North America HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 33 North America HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 34 US HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 35 US HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 36 US HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 37 Canada HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 38 Canada HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 39 Canada HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 40 Europe HIV and HBV Therapies Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 41 Europe HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 42 Europe HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 43 Germany HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 44 Germany HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 45 Germany HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 46 UK HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 47 UK HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 48 UK HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 49 France HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 50 France HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 51 France HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 52 Italy HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 53 Italy HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 54 Italy HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 55 Spain HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 56 Spain HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 57 Spain HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 58 Russia HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 59 Russia HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 60 Russia HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 61 Rest of Europe HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 62 Rest of Europe HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 63 Rest of Europe HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 64 Asia Pacific HIV and HBV Therapies Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 65 Asia Pacific HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 66 Asia Pacific HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 67 Japan HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 68 Japan HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 69 Japan HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 70 China HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 71 China HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 72 China HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 73 India HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 74 India HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 75 India HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 76 South Korea HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 77 South Korea HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 78 South Korea HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 79 Australia HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 80 Australia HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 81 Australia HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 82 Rest of Asia Pacific HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 83 Rest of Asia Pacific HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 84 Rest of Asia Pacific HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 85 Latin America HIV and HBV Therapies Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 86 Latin America HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 87 Latin America HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 88 Brazil HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 89 Brazil HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 90 Brazil HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 91 Mexico HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 92 Mexico HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 93 Mexico HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 94 Rest of Latin America HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 95 Rest of LATAM HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 96 Rest of LATAM HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 97 MEA HIV and HBV Therapies Market, By Country, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 98 MEA HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 99 MEA HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 100 South Africa HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 101 South Africa HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 102 South Africa HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 103 GCC HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 104 GCC HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 105 GCC HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 106 Rest of MEA HIV and HBV Therapies Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 107 Rest of MEA HIV and HBV Therapies Drug Class Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 108 Rest of MEA HIV and HBV Therapies Distribution Channel Market, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Table 109 Key Business Strategies Adopted by Key Players in Global HIV and HBV Therapies Market
  • Table 110 Pfizer: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 Pfizer: Product Benchmarking
  • Table 112 Merck: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Merck: Product Benchmarking
  • Table 114 Merck: Strategic Outlook
  • Table 115 GSK: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 116 GSK: Product Benchmarking
  • Table 117 GSK: Strategic Outlook
  • Table 118 AbbVie: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
  • Table 119 AbbVie: Product Benchmarking
  • Table 120 AbbVie: Strategic Outlook
  • Table 121 Boehringer Ingelheim: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 122 Boehringer Ingelheim: Product Benchmarking
  • Table 123 Gilead Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 124 Gilead Sciences: Product Benchmarking
  • Table 125 Gilead Sciences: Strategic Outlook
  • Table 126 Janssen Pharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 127 Janssen Pharma: Product Benchmarking
  • Table 128 Janssen Pharma: Strategic Outlook
  • Table 129 Teva: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 130 Teva: Product Benchmarking
  • Table 131 Teva: Strategic Outlook
  • Table 132 BMS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
  • Table 133 BMS: Product Benchmarking
  • Table 134 BMS: Strategic Outlook
  • Table 135 Arbutus Biopharma: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website)
  • Table 136 ARBUTUS BIOPHARMA: Product Benchmarking
  • Table 137 ARBUTUS BIOPHARMA: Strategic Outlook
  •  

List of Figures

  • Figure 1 Global HIV and HBV Therapies Market Segmentation
  • Figure 2 Global HIV and HBV Therapies Market Forecast by Region: Market Attractiveness Index
  • Figure 3 Global HIV and HBV Therapies Market by Drug Class: Market Attractiveness Index
  • Figure 4 Global HIV and HBV Therapies Market by Distribution Channel: Market Attractiveness Index
  • Figure 5 Global HIV and HBV Therapies Market: Market Dynamics
  • Figure 6 Global COVID Impact Analysis: HIV and HBV Therapies Market Recovery Scenarios
  • Figure 7 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): "V" Shaped Recovery
  • Figure 8 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): "U" Shaped Recovery
  • Figure 9 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): "W" Shaped Recovery
  • Figure 10 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)): "L" Shaped Recovery
  • Figure 11 Global HIV and HBV Therapies Market: Porter's Five Forces Analysis
  • Figure 12 Global HIV and HBV Therapies Market Forecast by Drug Class 2022, 2027, 2032 (Revenue, CAGR%)
  • Figure 13 Global HIV and HBV Therapies Market Share Forecast by Drug Class, 2022, 2027, 2032 (%)
  • Figure 14 Global HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 15 Combination Therapies Market Forecast by Region, 2022-2032 (US$ billion)
  • Figure 16 Combination Therapies Market Share Forecast by Region, 2022-2032 (%)
  • Figure 17 Nucleoside and Non-nucleoside RTIs Market Forecast by Region, 2022-2032 (US$ billion)
  • Figure 18 Nucleoside and Non-nucleoside RTIs Market Share Forecast by Region, 2022-2032 (%)
  • Figure 19 Integrase inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
  • Figure 20 Integrase inhibitors Market Share Forecast by Region, 2022-2032 (%)
  • Figure 21 Protease Inhibitors Market Forecast by Region, 2022-2032 (US$ billion)
  • Figure 22 Protease Inhibitors Market Share Forecast by Region, 2022-2032 (%)
  • Figure 23 Other Drug Class Market Forecast by Region, 2022-2032 (US$ billion)
  • Figure 24 Other Drug Class Market Share Forecast by Region, 2022-2032 (%)
  • Figure 25 Global HIV and HBV Therapies Market Forecast by Distribution Channel 2022, 2027, 2032 (Revenue, CAGR%)
  • Figure 26 Global HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 27 Global HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022, 2032 (%)
  • Figure 28 Hospital pharmacies Market Forecast by Region, 2022-2032 (US$ billion)
  • Figure 29 Hospital pharmacies Market Share Forecast by Region, 2022-2032 (%)
  • Figure 30 Retail pharmacies Market Forecast by Region, 2022-2032 (US$ billion)
  • Figure 31 Retail pharmacies Market Share Forecast by Region, 2022-2032 (%)
  • Figure 32 Online Pharmacies Market Forecast by Region, 2022-2032 (US$ billion)
  • Figure 33 Online Pharmacies Market Share Forecast by Region, 2022-2032 (%)
  • Figure 34 Global HIV and HBV Therapies Market Forecast by Region 2022, 2027, 2032 (Revenue), C
  • Figure 35 Global HIV and HBV Therapies Market Share Forecast by Region 2022, 2027, 2032(%)
  • Figure 36 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%))
  • Figure 37 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): "V" Shaped Recovery
  • Figure 38 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): "U" Shaped Recovery
  • Figure 39 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): "W" Shaped Recovery
  • Figure 40 Global HIV and HBV Therapies Market by Region, 2022-2032 (US$ Bn, AGR (%), CAGR (%)): "L" Shaped Recovery
  • Figure 41 North America HIV and HBV Therapies Market Attractiveness Index
  • Figure 42 North America HIV and HBV Therapies Market by Region, 2022, 2027 & 2032 (US$ billion)
  • Figure 43 North America HIV and HBV Therapies Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
  • Figure 44 North America HIV and HBV Therapies Market Share Forecast by Country, 2022 & 2032 (%)
  • Figure 45 North America HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 46 North America HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 47 North America HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 48 North America HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 49 U.S. HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 50 U.S. HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 51 U.S. HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 52 U.S. HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 53 U.S. HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 54 Canada HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 55 Canada HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 56 Canada HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 57 Canada HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 58 Canada HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 59 Europe HIV and HBV Therapies Market Attractiveness Index
  • Figure 60 Europe HIV and HBV Therapies Market by Region, 2022, 2027 & 2032 (US$ billion)
  • Figure 61 Europe HIV and HBV Therapies Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
  • Figure 62 Europe HIV and HBV Therapies Market Share Forecast by Country, 2022 & 2032 (%)
  • Figure 63 Europe HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 64 North America HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 65 Europe HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 66 Europe HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 67 Germany HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 68 Germany HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 69 Germany HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 70 Germany HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 71 Germany HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 72 UK HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 73 U.K. HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 74 U.K. HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 75 U.K. HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 76 U.K. HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 77 France HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 78 France HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 79 France HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 80 France HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 81 France HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 82 Italy HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 83 Italy HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 84 Italy HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 85 Italy HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 86 Italy HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 87 Spain HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 88 Spain HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 89 Spain HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 90 Spain HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 91 Spain HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 92 Russia HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 93 Russia HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 94 Russia HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 95 Russia HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 96 Russia HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 97 Rest of Europe HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 98 Rest of Europe HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 99 Rest of Europe HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 100 Rest of Europe HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 101 Rest of Europe HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 102 Asia Pacific HIV and HBV Therapies Market Attractiveness Index
  • Figure 103 Asia Pacific HIV and HBV Therapies Market by Region, 2022, 2027 & 2032 (US$ billion)
  • Figure 104 Asia Pacific HIV and HBV Therapies Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
  • Figure 105 Asia Pacific HIV and HBV Therapies Market Share Forecast by Country, 2022 & 2032 (%)
  • Figure 106 Asia Pacific HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 107 Asia Pacific HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 108 Asia Pacific HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 109 Asia Pacific HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 110 Japan HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 111 Japan HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 112 Japan HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 113 Japan HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 114 Japan HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 115 China HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 116 China HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 117 China HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 118 China HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 119 China HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 120 India HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 121 India HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 122 India HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 123 India HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 124 India HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 125 South Korea HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 126 South Korea HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 127 South Korea HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 128 South Korea HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 129 South Korea HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 130 Australia HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 131 Australia HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 132 Australia HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 133 Australia HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 134 Australia HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 135 Rest of Asia Pacific HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 136 Rest of APAC HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 137 Rest of APAC HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 138 Rest of APAC HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 139 Rest of APAC HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 140 Latin America HIV and HBV Therapies Market Attractiveness Index
  • Figure 141 Latin America HIV and HBV Therapies Market by Region, 2022, 2027 & 2032 (US$ billion)
  • Figure 142 Latin America HIV and HBV Therapies Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
  • Figure 143 Latin America HIV and HBV Therapies Market Share Forecast by Country, 2022 & 2032 (%)
  • Figure 144 Latin America HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 145 Latin America HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 146 Latin America HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 147 Latin America HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 148 Brazil HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 149 Brazil HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 150 Brazil HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 151 Brazil HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 152 Brazil HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 153 Mexico HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 154 Mexico HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 155 Mexico HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 156 Mexico HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 157 Mexico HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 158 Rest of LATAM HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 159 Rest of LATAM HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 160 Rest of LATAM HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 161 Rest of LATAM HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 162 Rest of LATAM HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 163 MEA HIV and HBV Therapies Market Attractiveness Index
  • Figure 164 MEA HIV and HBV Therapies Market by Region, 2022, 2027 & 2032 (US$ billion)
  • Figure 165 MEA HIV and HBV Therapies Market Forecast by Country, 2022-2032 (US$ billion, AGR %)
  • Figure 166 MEA HIV and HBV Therapies Market Share Forecast by Country, 2022 & 2032 (%)
  • Figure 167 MEA HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 168 MEA HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 169 MEA HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 170 MEA HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 171 South Africa HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 172 South Africa HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 173 South Africa HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 174 South Africa HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 175 South Africa HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 176 GCC HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 177 GCC HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 178 GCC HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 179 GCC HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 180 GCC HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 181 Rest of MEA HIV and HBV Therapies Market Forecast, 2022-2032 (US$ billion, AGR %)
  • Figure 182 Rest of MEA HIV and HBV Therapies Market Forecast by Drug Class, 2022-2032 (US$ billion, AGR %)
  • Figure 183 Rest of MEA HIV and HBV Therapies Market Share Forecast by Drug Class, 2022 & 2032 (%)
  • Figure 184 Rest of MEA HIV and HBV Therapies Market Forecast by Distribution Channel, 2022-2032 (US$ billion, AGR %)
  • Figure 185 Rest of MEA HIV and HBV Therapies Market Share Forecast by Distribution Channel, 2022 & 2032 (%)
  • Figure 186 Global HIV and HBV Therapies Market: Company Share Analysis, 2021
  • Figure 187 Pfizer: Net Revenue, 2019-2021 (US$ million, AGR %)
  • Figure 188 Pfizer: Regional Market Shares, 2021
  • Figure 189 Pfizer: Gross Profit, 2019-2021 (US$ million, AGR %)
  • Figure 190 Pfizer: R&D, 2019-2021 (US$ million, AGR %)
  • Figure 191 Merck: Net Revenue, 2019-2021 (US$ million, AGR %)
  • Figure 192 Merck: Regional Market Shares, 2021
  • Figure 193 Merck: Income from Continuing Operations before Taxes, 2019-2021 (US$ million, AGR %)
  • Figure 194 Merck: R&D, 2019-2021 (US$ million, AGR %)
  • Figure 195 GSK: Net Revenue, 2019-2021 (US$ million, AGR %)
  • Figure 196 GSK: Regional Market Shares, 2021
  • Figure 197 GSK: Gross Profit, 2019-2021 (US$ million, AGR %)
  • Figure 198 GSK: R&D, 2019-2021 (US$ million, AGR %)
  • Figure 199 AbbVie: Net Revenue, 2019-2021 (US$ million, AGR %)
  • Figure 200 AbbVie: Regional Market Shares, 2021
  • Figure 201 AbbVie: Operating Earnings, 2019-2021 (US$ million, AGR %)
  • Figure 202 AbbVie: R&D, 2019-2021 (US$ million, AGR %)
  • Figure 203 Boehringer Ingelheim: Net Revenue, 2019-2021 (US$ million, AGR %)
  • Figure 204 Boehringer Ingelheim: Regional Market Shares, 2021
  • Figure 205 Boehringer Ingelheim: Operating Income, 2019-2021 (US$ million, AGR %)
  • Figure 206 Boehringer Ingelheim: R&D, 2019-2021 (US$ million, AGR %)
  • Figure 207 Gilead Sciences: Net Revenue, 2019-2021 (US$ million, AGR %)
  • Figure 208 Gilead Sciences: Regional Market Shares, 2021
  • Figure 209 Gilead Sciences: Operating Profit, 2019-2021 (US$ million, AGR %)
  • Figure 210 Gilead Sciences: R&D, 2019-2021 (US$ million, AGR %)
  • Figure 211 Janssen Pharma: Net Revenue, 2019-2021 (US$ million, AGR %)
  • Figure 212 Janssen Pharma: Regional Market Shares, 2021
  • Figure 213 Janssen Pharma: Gross Profit, 2019-2021 (US$ million, AGR %)
  • Figure 214 Janssen Pharma: R&D, 2019-2021 (US$ million, AGR %)
  • Figure 215 Teva: Net Revenue, 2019-2021 (US$ million, AGR %)
  • Figure 216 Teva: Regional Market Shares, 2021
  • Figure 217 Teva: Gross Profit, 2019-2021 (US$ million, AGR %)
  • Figure 218 Teva: R&D, 2019-2021 (US$ million, AGR %)
  • Figure 219 BMS: Net Revenue, 2019-2021 (US$ million, AGR %)
  • Figure 220 BMS: Regional Market Shares, 2021
  • Figure 221 BMS: Net Earnings, 2019-2021 (US$ million, AGR %)
  • Figure 222 BMS: R&D, 2019-2021 (US$ million, AGR %)
  • Figure 223 Arbutus Biopharma: Net Revenue, 2019-2021 (US$ million, AGR %)
  • Figure 224 Arbutus Biopharma: Comprehensive Loss, 2019-2021 (US$ million, AGR %)
  • Figure 225 Arbutus Biopharma: R&D, 2019-2021 (US$ million, AGR %)"
  • "List of Tables
  • Table 1 Global Critical Infrastructure Protection M
目次
Product Code: PHA1202

The global HIV and HBV Therapies market is estimated to be valued at US$36.2 billion in 2022 and is projected to grow at a CAGR of 6.5% during the forecast period 2022-2032.

“The HIV and HBV Therapies Market Report 2022-2032”: This report will prove valuable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Factors Such as Rising Prevalence of HIV and HBV, High Investment in R&D, and Growing Government Support Are Driving the Market Growth

Some of the major forces propelling the global HIV and HBV therapies market include rising prevalence of HIV and HBV, high investment in R&D, and growing government support. Robust government support for HIV and HBV therapies research is one of the major factors that propel the market growth. There is a need for significant collaborations among the pharmaceutical industry, foundations, patient advocacy organizations, academic and public researchers and financing programs, regulatory researchers and reimbursement organizations to identify and develop solutions for the unmet diagnostic and therapy requirements. Increasing prevalence of HIV and Hepatitis has urged a need for new treatment options. Hence, government organizations are taking efforts to address the unmet needs and provide advanced care. Major challenge for most of the HIV and HBV therapies in R&D is the large number of investments and research required and the amount of vast clinical aspects of these organisms and diseases. The challenge becomes severed due to the changing nature of antivirals and hence the need for long-term follow-up is crucial. This aspect is predicted to hinder the market over the forecast period.

Regulation Challenges

FDA drug approvals usually involve long and tedious processes before the product is finally commercialized. This usually proves to be a challenge for companies that are involved in intense R&D bringing new products into the market. Safety and usage of the product are completely verified by authorities before commercializing it to the general masses. This requires large amount of investments.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the HIV and HBV Therapies market evolving?
  • What is driving and restraining the HIV and HBV Therapies market?
  • How will each HIV and HBV Therapies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
  • How will the market shares for each HIV and HBV Therapies submarket develop from 2022 to 2032?
  • What will be the main driver for the overall market from 2022 to 2032?
  • Will leading HIV and HBV Therapies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the HIV and HBV Therapies projects for these leading companies?
  • How will the industry evolve during the period between 2020 and 2032? What are the implications of HIV and HBV Therapies projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the HIV and HBV Therapies market?
  • Where is the HIV and HBV Therapies market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the HIV and HBV Therapies market today, and over the next 10 years:

  • Our 353- page report provides 137 tables, 225 charts, and graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the HIV and HBV Therapies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising HIV and HBV Therapies prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Drug Class Outlook

  • Combination Therapies
  • Nucleoside and Non-nucleoside RTIs
  • Integrase Inhibitors
  • Protease Inhibitors
  • Others

Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20+ leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • Spain
  • United Kingdom
  • France
  • Italy
  • Russia
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

LATAM

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • South Africa
  • GCC
  • Rest of MEA

The report also includes profiles for some of the leading companies in the HIV and HBV Therapies Market, 2022 to 2032, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • Pfizer
  • Merck
  • GSK
  • AbbVie
  • Boehringer Ingelheim
  • Gilead Sciences
  • Janssen Pharmaceutical
  • Teva
  • BMS
  • Arbustus Biopharma

Overall world revenue for HIV and HBV Therapies Market, 2022 to 2032 in terms of value the market will surpass US$36.2 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the HIV and HBV Therapies Market, 2022 to 2032 report help you?

In summary, our 350+ page report provides you with the following knowledge:

  • Revenue forecasts to 2032 for HIV and HBV Therapies Market, 2022 to 2032 Market, with forecasts for drug class, distribution channel, and company size, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2032 for four regional and 20 key national markets - See forecasts for the HIV and HBV Therapies Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the HIV and HBV Therapies Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the HIV and HBV Therapies Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to HIV and HBV Therapies Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered By This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

  • 2.1 Geographical Snapshot: Global HIV and HBV Therapies Market
  • 2.2 Drug Class Segment: Market Attractiveness Index
  • 2.3 Distribution Channel Segment: Market Attractiveness Index

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
    • 3.2.2 Market Restraining Factors
    • 3.2.3 Market Opportunities
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Supplier Power
    • 3.4.2 Buyer Power
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants

4 Global HIV and HBV Therapies Market Analysis by Drug Class

  • 4.1 Key Findings
  • 4.2 Drug Class Segment Growth Prospects
  • 4.3 Global HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
  • 4.4 Combination Therapies
    • 4.4.1 Combination Therapies Market Forecast by Region, 2022-2032 (US$ Bn)
    • 4.4.2 Combination Therapies Market Share by Region, 2022-2032 (%)
  • 4.5 Nucleoside and Non-nucleoside RTIs
    • 4.5.1 Nucleoside and Non-nucleoside RTIs Market Forecast by Region, 2022-2032 (US$ Bn)
    • 4.5.2 Nucleoside and Non-nucleoside RTIs Market Share by Region, 2022-2032 (%)
  • 4.6 Integrase Inhibitors
    • 4.6.1 Integrase inhibitors Market Forecast by Region, 2022-2032 (US$ Bn)
    • 4.6.2 Integrase inhibitors Market Share by Region, 2022-2032 (%)
  • 4.7 Protease Inhibitors
    • 4.7.1 Protease Inhibitors Market Forecast by Region, 2022-2032 (US$ Bn)
    • 4.7.2 Protease Inhibitors Market Share by Region, 2022-2032 (%)
  • 4.8 Other Drug class
    • 4.8.1 Other Drug Class Market Forecast by Region, 2022-2032 (US$ Bn)
    • 4.8.2 Other Drug Class Market Share by Region, 2022-2032 (%)

5 Global HIV and HBV Therapies Market Analysis by Distribution Channel

  • 5.1 Key Findings
  • 5.2 Distribution Channel Segment Growth Prospects
  • 5.3 Global HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
  • 5.4 Global HIV and HBV Therapies Market Share by Distribution Channel, 2022 & 2032
  • 5.5 Hospital Pharmacies
    • 5.5.1 Hospital pharmacies Market Forecast by Region, 2022-2032 (US$ Bn)
    • 5.5.2 Hospital pharmacies Market Share by Region, 2022-2032 (%)
  • 5.6 Retail Pharmacies
    • 5.6.1 Retail pharmacies Market Forecast by Region, 2022-2032 (US$ Bn)
    • 5.6.2 Retail pharmacies Market Share by Region, 2022-2032 (%)
  • 5.7 Online Pharmacies
    • 5.7.1 Online Pharmacies Market Forecast by Region, 2022-2032 (US$ Bn)
    • 5.7.2 Online Pharmacies Market Share by Region, 2022-2032 (%)

6 Global HIV and HBV Therapies Market Pipeline Analysis

  • 6.1 Key Findings
  • 6.2 HIV Pipeline
  • 6.3 HBV Pipeline

7 Global HIV and HBV Therapies Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast
  • 7.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)

8 North America HIV and HBV Therapies Market Analysis

  • 8.1 Key Findings
  • 8.2 North America HIV and HBV Therapies Market Attractiveness Index
  • 8.3 North America HIV and HBV Therapies Market by Country, 2022, 2027 & 2032 (US$ bn)
  • 8.4 North America HIV and HBV Therapies Market Size Estimation and Forecast by Country
  • 8.5 North America HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
  • 8.6 North America HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
  • 8.7 U.S.
    • 8.7.1 U.S. HIV and HBV Therapies Market by Drug Class
    • 8.7.2 U.S. HIV and HBV Therapies Market by Distribution Channel
  • 8.8 Canada
    • 8.8.1 Canada HIV and HBV Therapies Market by Drug Class
    • 8.8.2 Canada HIV and HBV Therapies Market by Distribution Channel

9 Europe HIV and HBV Therapies Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe HIV and HBV Therapies Market Attractiveness Index
  • 9.3 Europe HIV and HBV Therapies Market by Country, 2022, 2027 & 2032 (US$ bn)
  • 9.4 Europe HIV and HBV Therapies Market Size Estimation and Forecast by Country
  • 9.5 Europe HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
  • 9.6 Europe HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
  • 9.7 Germany
    • 9.7.1 Germany HIV and HBV Therapies Market by Drug Class
    • 9.7.2 Germany HIV and HBV Therapies Market by Distribution Channel
  • 9.8 U.K.
    • 9.8.1 U.K. HIV and HBV Therapies Market by Drug Class
    • 9.8.2 U.K. HIV and HBV Therapies Market by Distribution Channel
  • 9.9 France
    • 9.9.1 France HIV and HBV Therapies Market by Drug Class
    • 9.9.2 France HIV and HBV Therapies Market by Distribution Channel
  • 9.10 Italy
    • 9.10.1 Italy HIV and HBV Therapies Market by Drug Class
    • 9.10.2 Italy HIV and HBV Therapies Market by Distribution Channel
  • 9.11 Spain
    • 9.11.1 Spain HIV and HBV Therapies Market by Drug Class
    • 9.11.2 Spain HIV and HBV Therapies Market by Distribution Channel
  • 9.12 Russia
    • 9.12.1 Russia HIV and HBV Therapies Market by Drug Class
    • 9.12.2 Russia HIV and HBV Therapies Market by Distribution Channel
  • 9.13 Rest of Europe
    • 9.13.1 Rest of Europe HIV and HBV Therapies Market by Drug Class
    • 9.13.2 Rest of Europe HIV and HBV Therapies Market by Distribution Channel

10 Asia Pacific HIV and HBV Therapies Market Analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific HIV and HBV Therapies Market Attractiveness Index
  • 10.3 Asia Pacific HIV and HBV Therapies Market by Country, 2022, 2027 & 2032 (US$ bn)
  • 10.4 Asia Pacific HIV and HBV Therapies Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
  • 10.6 Asia Pacific HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
  • 10.7 Japan
    • 10.7.1 Japan HIV and HBV Therapies Market by Drug Class
    • 10.7.2 Japan HIV and HBV Therapies Market by Distribution Channel
  • 10.8 China
    • 10.8.1 China HIV and HBV Therapies Market by Drug Class
    • 10.8.2 China HIV and HBV Therapies Market by Distribution Channel
  • 10.9 India
    • 10.9.1 India HIV and HBV Therapies Market by Drug Class
    • 10.9.2 India HIV and HBV Therapies Market by Distribution Channel
  • 10.10 South Korea
    • 10.10.1 South Korea HIV and HBV Therapies Market by Drug Class
    • 10.10.2 South Korea HIV and HBV Therapies Market by Distribution Channel
  • 10.11 Australia
    • 10.11.1 Australia HIV and HBV Therapies Market by Drug Class
    • 10.11.2 Australia HIV and HBV Therapies Market by Distribution Channel
  • 10.12 Rest of APAC
    • 10.12.1 Rest of APAC HIV and HBV Therapies Market by Drug Class
    • 10.12.2 Rest of APAC HIV and HBV Therapies Market by Distribution Channel

11 Latin America HIV and HBV Therapies Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America HIV and HBV Therapies Market Attractiveness Index
  • 11.3 Latin America HIV and HBV Therapies Market by Country, 2022, 2027 & 2032 (US$ bn)
  • 11.4 Latin America HIV and HBV Therapies Market Size Estimation and Forecast by Country
  • 11.5 Latin America HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
  • 11.6 Latin America HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
  • 11.7 Brazil
    • 11.7.1 Brazil HIV and HBV Therapies Market by Drug Class
    • 11.7.2 Brazil HIV and HBV Therapies Market by Distribution Channel
  • 11.8 Mexico
    • 11.8.1 Mexico HIV and HBV Therapies Market by Drug Class
    • 11.8.2 Mexico HIV and HBV Therapies Market by Distribution Channel
  • 11.9 Rest of Latin America
    • 11.9.1 Rest of LATAM HIV and HBV Therapies Market by Drug Class
    • 11.9.2 Rest of LATAM HIV and HBV Therapies Market by Distribution Channel

12 MEA HIV and HBV Therapies Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA HIV and HBV Therapies Market Attractiveness Index
  • 12.3 MEA HIV and HBV Therapies Market by Country, 2022, 2027 & 2032 (US$ bn)
  • 12.4 MEA HIV and HBV Therapies Market Size Estimation and Forecast by Country
  • 12.5 MEA HIV and HBV Therapies Market Size Estimation and Forecast by Drug Class
  • 12.6 MEA HIV and HBV Therapies Market Size Estimation and Forecast by Distribution Channel
  • 12.7 South Africa
    • 12.7.1 South Africa HIV and HBV Therapies Market by Drug Class
    • 12.7.2 South Africa HIV and HBV Therapies Market by Distribution Channel
  • 12.8 GCC
    • 12.8.1 GCC HIV and HBV Therapies Market by Drug Class
    • 12.8.2 GCC HIV and HBV Therapies Market by Distribution Channel
  • 12.9 Rest of MEA
    • 12.9.1 Rest of MEA HIV and HBV Therapies Market by Drug Class
    • 12.9.2 Rest of MEA HIV and HBV Therapies Market by Distribution Channel

13 Competitive Landscape

  • 13.1 Company Share Analysis
  • 13.2 Key Business Strategy Analysis

14 Company Profiles

  • 14.1 Pfizer
    • 14.1.1 Company Snapshot
    • 14.1.2 Company Overview
    • 14.1.3 Financial Analysis
    • 14.1.4 Product Benchmarking
    • 14.1.5 Strategic Outlook
  • 14.2 Merck
    • 14.2.1 Company Snapshot
    • 14.2.2 Company Overview
    • 14.2.3 Financial Analysis
    • 14.2.4 Product Benchmarking
    • 14.2.5 Strategic Outlook
  • 14.3 GSK
    • 14.3.1 Company Snapshot
    • 14.3.2 Company Overview
    • 14.3.3 Financial Analysis
    • 14.3.4 Product Benchmarking
    • 14.3.5 Strategic Outlook
  • 14.4 AbbVie
    • 14.4.1 Company Snapshot
    • 14.4.2 Company Overview
    • 14.4.3 Financial Analysis
    • 14.4.4 Product Benchmarking
    • 14.4.5 Strategic Outlook
  • 14.5 Boehringer Ingelheim
    • 14.5.1 Company Snapshot
    • 14.5.2 Company Overview
    • 14.5.3 Financial Analysis
    • 14.5.4 Product Benchmarking
    • 14.5.5 Strategic Outlook
  • 14.6 Gilead Sciences
    • 14.6.1 Company Snapshot
    • 14.6.2 Company Overview
    • 14.6.3 Financial Analysis
    • 14.6.4 Product Benchmarking
    • 14.6.5 Strategic Outlook
  • 14.7 Janssen Pharma
    • 14.7.1 Company Snapshot
    • 14.7.2 Company Overview
    • 14.7.3 Financial Analysis
    • 14.7.4 Product Benchmarking
    • 14.7.5 Strategic Outlook
  • 14.8 Teva
    • 14.8.1 Company Snapshot
    • 14.8.2 Company Overview
    • 14.8.3 Financial Analysis
    • 14.8.4 Product Benchmarking
    • 14.8.5 Strategic Outlook
  • 14.9 BMS
    • 14.9.1 Company Snapshot
    • 14.9.2 Company Overview
    • 14.9.3 Financial Analysis
    • 14.9.4 Product Benchmarking
    • 14.9.5 Strategic Outlook
  • 14.10 Arbutus Biopharma
    • 14.10.1 Company Snapshot
    • 14.10.2 Company Overview
    • 14.10.3 Financial Analysis
    • 14.10.4 Product Benchmarking
    • 14.10.5 Strategic Outlook

15 Conclusion and Recommendations

  • 15.1 Concluding Remarks from
  • 15.2 Recommendations for Market Players